Multistakeholder insights on digital therapeutics: balancing evidence and value to meet patient needs

1 Jun 2023

Written by Chris Sampson (Office of Health Economics), Elise Berliner (Cerner Enviza), Karen Robinson (Johns Hopkins University), Suhas Krishna (Bristol Myers Squibb)

Events coverage Health data Interviews ISPOR

Chris Sampson, Karen Robinson, Suhas Krishna and Elise Berliner discussing digital therapeutics

Digital therapeutics (DTx), also known as digital health technologies (DHTs), are having a potentially transformative impact on healthcare, offering alternatives to traditional treatments by providing evidence-based interventions that are easily accessible, cost-effective, and customizable to individual needs. However, much uncertainty remains with differing needs from multiple stakeholders driving the discussion around the topic. In this interview with Elise Berliner (Cerner Enviza, Kansas City, MO, USA), Suhas Krishna (Bristol Myers Squibb, New York, NY, USA), Karen Robinson (Johns Hopkins University, Baltimore, MD, USA) and Chris Sampson (Office of Health Economics, London, UK) we explore this topic, which was also the focus...